Molecular Health Announces Appointment of Ashiq H. Khan, PhD, as Vice President (In Silico Biomedicine) | Molecular Health

Newsroom

All news

Molecular Health Announces Appointment of Ashiq H. Khan, PhD, as Vice President (In Silico Biomedicine)

Heidelberg, Germany – October 1, 2019 – Molecular Health, a leading company in the field of data science for precision medicine and specializing in the development of products and services leveraging its proprietary biomedicine technology platform Dataome, today announced the appointment of Dr. Ashiq H. Khan, as Vice President (In Silico Biomedicine).

 

Dr. Khan comes to Molecular Health with 13 years of outstanding experience in Healthcare, Research and Analytics, and Digital Transformation Strategy. Dr. Khan holds PhD in Molecular Neurobiology and has conducted research both at the University of Cologne and Harvard University USA. Dr. Khan completed his postdoctoral training from Yale University USA. He is an internationally recognized author with high impact scientific publications, a keynote speaker, and a frequent guest in media contributing to the topics of Healthcare, Neuroscience, and Technology.

 

In his previous executive roles, Dr. Khan has been leading a number of strategic transformations projects globally in the Pharma and Technology industry. Based on his more than decade-long expertise in leadership and an exceptional understanding of how the business and technology work together, he will also help develop the strategic direction of Molecular Health to successfully navigate the company in the imminent era of data-driven drug development and precision medicine.

 

Dr. Friedrich von Bohlen, Co-founder, and CEO of Molecular Health said:” We are very pleased to have Dr. Khan join our team. His experience in successfully leading strategic digital transformations programs in the global Pharma and Technology industry will be a great asset for Molecular Health GmbH.”

 

Dr. Khan adds: “I am very excited to join the Molecular Health team. Molecular Health has the ability and competitive edge of industry-validated mature technology to drive a paradigm shift in drug development and precision medicine – creating value for diverse stakeholders such as Pharma, Biotechs, CROs, Patients, Governments and Investors”.